SIGA publishes investor presentation on TPOXX smallpox antiviral franchise and growth strategy

• SIGA Technologies outlined a strategy to extend its TPOXX smallpox franchise through new indications, including post-exposure prophylaxis, and new formulations.
• Presentation highlighted TPOXX regulatory clearances across the U.S., Canada, Europe, the UK, and Japan, positioning it as a core biodefense product.
• Company cited about $980 million in product revenue during 2020-2025, citing robust gross margins and about $390 million in pre-tax operating income.
• Government contracting remained central, with BARDA procurement contracts totaling $1.01 billion across 2011-2018 and 2018-2026, both fully delivered.
• Balance sheet messaging emphasized disciplined cash use, no debt, and a $43 million cash dividend paid in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SIGA Technologies Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.